A phase II clinical trial is currently under way testing ruxolitinib in CRLF2/JAK2 mutant Ph-like B-ALL, further highlighting the critical need to elucidate the relevance of JAK2 as a therapeutic target in this disease (ClinicalTrials.gov identifier: NCT02723994). This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.